Ganjam V Kalpana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9149529/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell, 1993, 73, 1067-1078.	13.5	817
2	[25] Genetic systems for mycobacteria. Methods in Enzymology, 1991, 204, 537-555.	0.4	426
3	c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nature Genetics, 1999, 22, 102-105.	9.4	348
4	Cell Cycle Arrest and Repression of Cyclin D1 Transcription by INI1/hSNF5. Molecular and Cellular Biology, 2002, 22, 5975-5988.	1.1	223
5	Cytoplasmic Recruitment of INI1 and PML on Incoming HIV Preintegration Complexes. Molecular Cell, 2001, 7, 1245-1254.	4.5	216
6	Human Immunodeficiency Virus Type 1 Integrase Protein Promotes Reverse Transcription through Specific Interactions with the Nucleoprotein Reverse Transcription Complex. Journal of Virology, 1999, 73, 2126-2135.	1.5	181
7	Auxotrophic vaccines for tuberculosis. Nature Medicine, 1996, 2, 334-337.	15.2	166
8	Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nature Medicine, 2001, 7, 920-926.	15.2	124
9	Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA. Nature, 1999, 399, 487-491.	13.7	109
10	Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12129-12134.	3.3	109
11	The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor. Molecular Endocrinology, 2008, 22, 838-857.	3.7	107
12	Interaction between Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Integrase Proteins. Journal of Virology, 2004, 78, 5056-5067.	1.5	103
13	Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs. Clinical Cancer Research, 2007, 13, 2488-2495.	3.2	100
14	<i>Aurora A</i> Is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival. Cancer Research, 2011, 71, 3225-3235.	0.4	90
15	A masked NES in INI1/hSNF5 mediates hCRM1-dependent nuclear export: implications for tumorigenesis. EMBO Journal, 2002, 21, 31-42.	3.5	87
16	Homodimerization of Human Bilirubin-Uridine-diphosphoglucuronate Glucuronosyltransferase-1 (UGT1A1) and Its Functional Implications. Journal of Biological Chemistry, 2001, 276, 42108-42115.	1.6	83
17	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039.	3.2	74
18	Specificity of Interaction of INI1/hSNF5 with Retroviral Integrases and Its Functional Significance. Journal of Virology, 2004, 78, 2222-2231.	1.5	66

GANJAM V KALPANA

#	Article	IF	CITATIONS
19	Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents. Clinical Cancer Research, 2005, 11, 6359-6369.	3.2	65
20	Dopamine Receptor Activation Increases HIV Entry into Primary Human Macrophages. PLoS ONE, 2014, 9, e108232.	1.1	63
21	Recruitment of a SAP18-HDAC1 Complex into HIV-1 Virions and Its Requirement for Viral Replication. PLoS Pathogens, 2009, 5, e1000463.	2.1	53
22	INI1 Induces Interferon Signaling and Spindle Checkpoint in Rhabdoid Tumors. Clinical Cancer Research, 2007, 13, 4721-4730.	3.2	43
23	Rhabdoid Tumor Growth is Inhibited by Flavopiridol. Clinical Cancer Research, 2008, 14, 523-532.	3.2	41
24	Therapeutically targeting cyclin D1 in primary tumors arising from loss of <i>Ini1</i> . Proceedings of the United States of America, 2011, 108, 319-324.	3.3	40
25	Dynamics of Virus-Host Interplay in HIV-1 Replication. Current HIV Research, 2006, 4, 117-130.	0.2	30
26	Isolation and Characterization of an Oligomerization-Negative Mutant of HIV-1 Integrase. Virology, 1999, 259, 274-285.	1.1	29
27	HIV-1 replication in cell lines harboring INI1/hSNF5 mutations. Retrovirology, 2006, 3, 56.	0.9	29
28	Multimerization and DNA Binding Properties of INI1/hSNF5 and Its Functional Significance. Journal of Biological Chemistry, 2009, 284, 19903-19914.	1.6	29
29	Retroviral Vectors for Liver-directed Gene Therapy. Seminars in Liver Disease, 1999, 19, 27-37.	1.8	28
30	Novel Yeast-based Strategy Unveils Antagonist Binding Regions on the Nuclear Xenobiotic Receptor PXR. Journal of Biological Chemistry, 2013, 288, 13655-13668.	1.6	28
31	CCL2 mobilizes ALIX to facilitate Gag-p6 mediated HIV-1 virion release. ELife, 2019, 8, .	2.8	22
32	Design and synthesis of 4-HPR derivatives for rhabdoid tumors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3805-3808.	1.0	19
33	Inhibition of Early Stages of HIV-1 Assembly by INI1/hSNF5 Transdominant Negative Mutant S6. Journal of Virology, 2011, 85, 2254-2265.	1.5	19
34	Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer, 2010, 10, 634.	1.1	16
35	Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4177-4180.	1.0	14
36	INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo. Retrovirology, 2013, 10, 66.	0.9	13

GANJAM V KALPANA

#	Article	IF	CITATIONS
37	Reverse Two-Hybrid Screening to Analyze Protein–Protein Interaction of HIV-1 Viral and Cellular Proteins. Methods in Molecular Biology, 2009, 485, 271-293.	0.4	12
38	In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines. Cancer Cell International, 2011, 11, 34.	1.8	9
39	INI1/SMARCB1 Rpt1 domain mimics TAR RNA in binding to integrase to facilitate HIV-1 replication. Nature Communications, 2021, 12, 2743.	5.8	9
40	Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication. Retrovirology, 2008, 5, 102.	0.9	6
41	An Essential Role of INI1/hSNF5 Chromatin Remodeling Protein in HIV-1 Posttranscriptional Events and Gag/Gag-Pol Stability. Journal of Virology, 2016, 90, 9889-9904.	1.5	6
42	Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. Acta Neuropathologica, 2021, 142, 361-374.	3.9	6
43	FISHing Out the Hidden Enemy: Advances in Detecting and Measuring Latent HIV-Infected Cells. MBio, 2017, 8, .	1.8	4
44	Development of Targeted Therapies for Rhabdoid Tumors Based on the Functions of INI1/hSNF5 Tumor Suppressor. , 2010, , 305-330.		2
45	Quantification of HIV-1 Gag Localization Within Virus Producer Cells. Methods in Molecular Biology, 2016, 1354, 165-174.	0.4	2
46	Computational modeling of Repeat1 region of INI1/hSNF5: An evolutionary link with ubiquitin. Protein Science, 2016, 25, 1593-1604.	3.1	1